The Development of Pharmacy: Setting the Scene

1990 ◽  
pp. 7-15
Author(s):  
Geoffrey Harding ◽  
Sarah Nettleton ◽  
Kevin Taylor
Keyword(s):  
2003 ◽  
Vol 37 (1) ◽  
pp. 40-46
Author(s):  
Rosemin Kassam ◽  
Linda G Martin ◽  
Karen B Farris ◽  
Homero A Monsanto ◽  
Jean-Marie Kaiser

Background The medication appropriateness index (MAI) has demonstrated reliability in selected outpatient clinics where medical data were easily accessible from medical charts. However, its use in the community setting where patient data may be limited has not been examined. Objective To evaluate the usefulness of a modified MAI for use in the community pharmacy setting by testing interrater reliability using 3 different rating schemes. Methods Two raters evaluated 160 medications for 32 elderly ambulatory patients. Patient information was acquired using community pharmacist-collected medication histories. A summated MAI score, percent agreement, κ, positive agreement, negative agreement, and intraclass correlation coefficient were calculated for each criterion using 3 scoring schemes. A paired samples t-test (95% CI) was used to test interrater reliability. Results The κ statistics were >0.75 for indication and effectiveness, but good (0.41–0.66) for the remaining criteria using the Hanlon scoring scheme. The intraclass coefficients (0.82, 0.86, 0.87) and overall κ (0.65, 0.66, 0.61) were similar for the 3 schemes. Conclusions This study suggests that the modified MAI has the potential to detect medication appropriateness and inappropriateness in the community pharmacy setting; however, it is not without limitations. Because the MAI has the most clinimetric and psychometric data available, the instrument should be studied further to increase its reliability and generalizability.


2017 ◽  
Vol 103 (6) ◽  
pp. 1052-1060 ◽  
Author(s):  
Paul Dillon ◽  
Derek Stewart ◽  
Susan M. Smith ◽  
Paul Gallagher ◽  
Gráinne Cousins

2010 ◽  
Vol 20 (4) ◽  
pp. 399-404 ◽  
Author(s):  
Søren Troels Christensen ◽  
Birthe Søndergaard ◽  
Per Hartvig Honoré ◽  
Ole Jannik Bjerrum

2017 ◽  
Vol 57 (2) ◽  
pp. S10-S11 ◽  
Author(s):  
Traci C. Green ◽  
Nathan Potter ◽  
Jeffrey Bratberg
Keyword(s):  

2021 ◽  
Vol 17 (6) ◽  
pp. 445-453
Author(s):  
Angelina Vascimini, PharmD ◽  
Kevin Duane, PharmD ◽  
Stacey Curtis, PharmD

Objective: The opioid epidemic is frequently discussed including the staggering numbers involved with coprescribing opioids and benzodiazepines associated with death. Community pharmacists, with the help of a system intervention, have a unique opportunity to help reduce the coprescribing of benzodiazepines and opioids and reduce the associated risk of death.Design: A single center retrospective chart review was conducted after a system intervention was placed, as a quality improvement project, from November 2019 to May 2020.Setting: Independent community pharmacy.Patients/participants: Data included demographics, dosing of each medication pre- and post-intervention, and naloxone status.Main outcome(s) measures: The primary outcome evaluated was reduction in dose/discontinuation of these prescriptions. The secondary outcome evaluated was the number of naloxone prescriptions ordered per protocol and picked up.Results: The primary outcome did not show statistical difference; however, the secondary outcomes showed statistical significance.Conclusion: In conclusion, community pharmacists, with the help of evolving technologies, can reduce harm associated with the coprescribing of benzodiazepines and opioids.


2020 ◽  
Vol 73 ◽  
pp. S324
Author(s):  
Nicki Palmer ◽  
Paul John ◽  
Kerry Rockey ◽  
Rhys Oakley ◽  
Brendan Healy

Sign in / Sign up

Export Citation Format

Share Document